Steven Park, MD

About Me

I am a physician scientist who specializes in lymphoma. I obtained a BA in Integrative Biology at University of California, Berkeley where I received the Highest Distinction in General Scholarship, followed by an MD degree at University of California, Davis, School of Medicine. I received my residency training at University of Washington and completed a fellowship in Hematology and Oncology at University of Washington and Fred Hutchinson Cancer Research Center. I am the recipient of Lymphoma Research Foundation Fellowship Award and American Cancer Society Mentored Research Scholar Grant (ACS-MRSG) Award In Tumor Biology and Genomics. I was also elected as the HemOnc Today’s NextGen Innovator. My research is currently being supported by Leukemia Lymphoma Society Translational Research Program (LLS-TRP), Follicular Lymphoma Foundation, and Institute for Follicular Lymphoma Innovation.

I am currently the Vice Chair for Research in the Department of Hematologic Oncology and Blood Disorders and also Co-Leader for the Experimental Therapeutics and Applied Sciences (ETAS) Program at Wake Forest Baptist Comprehensive Cancer Center. I've been the principal investigator of numerous clinical trials and translational research projects, and as a medical oncologist, I am dedicated to providing the best care to my patients.

Research Lab

Steven Park Lab - Focused on small molecule-based targeted therapy and cellular immunotherapy in lymphoma

Research

Publications

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Blood Adv. 2023 Jun; 7(11):2287-2296.
A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, Tan X, Beaven A, Park SI. EJHaem. 2022 Aug; 3(3):734-738.
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Blood Adv. 2021 Dec; 5(23):5179-5189.
Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Moore DC, Soni AC, Hu B, Smith ET, Levine J, Moyo TK, Jacobs R, Ghosh N, Park SI. Br J Haematol. 2022 Feb; 196(4):e30-e33.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Am J Hematol. 2021 Nov; 96(11):1374-1384.

Technology Transfer and Commercialization

Research Focus Areas

Translation to Care

More Resources

Steven Park, MD

Research Interests

About Me

Research Lab